研究業績

脳神経内科

神経内科業績

  1. Isobe S, Ohashi N, Fujikura T, Tsuji T, Sakao Y, Yasuda H, Kato A, Miyajima H, Fujigaki Y: Disturbed circadian rhythm of the intrarenal renin-angiotensin system: relevant to nocturnal hypertension and renal damage. Clin Exp Nephrol 19(2):231-9,2015.
  2. Kagami T, Sugimoto M, Ichikawa H, Sahara S, Uotani T, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Furuta T: One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19. Eur J Clin Pharmacol 71:1467-75, 2015.
  3. Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Kagami T, Hamaya Y, Iwaizumi M, Osawa S,Sugimoto K, Miyajima H, Furuta T: Potent Gastric Acid Inhibition Over 24 Hours by 4-Times Daily Dosing of Esomeprazole 20 mg. Digestion 91: 277-85, 2015.
英文業績
  1. Isobe S, Ohashi N, Fujikura T, Tsuji T, Sakao Y, Yasuda H, Kato A, Miyajima H, Fujigaki Y: Disturbed circadian rhythm of the intrarenal renin-angiotensin system: relevant to nocturnal hypertension and renal damage. Clin Exp Nephrol 19(2):231-9,2015.
  2. Kagami T, Sugimoto M, Ichikawa H, Sahara S, Uotani T, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Sugimoto K, Miyajima H, Furuta T: One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19. Eur J Clin Pharmacol 71:1467-75, 2015.
  3. Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Kagami T, Hamaya Y, Iwaizumi M, Osawa S,Sugimoto K, Miyajima H, Furuta T: Potent Gastric Acid Inhibition Over 24 Hours by 4-Times Daily Dosing of Esomeprazole 20 mg. Digestion 91: 277-85, 2015.
  4. Ichikawa H, Sugimoto M, Uotani T, Sahara S, Yamade M, Iwaizumi M, Yamada T, Osawa S, Sugimoto K, Miyajima H, Yamaoka Y, Furuta T: Influence of prostate stem cell antigen gene polymorphisms on susceptibility to Helicobacter pylori-associated diseases: a case-control study. Helicobacter 20:106-13, 2015.
  5. Yoshizawa Y, Sugimoto M, Sato Y, Sahara S, Ichikawa H, Kagami T, Hosoda Y, Kimata M, Tamura S, Kobayashi Y, Osawa S, Sugimoto K, Miyajima H, Furuta T: Factors associated with healing of artificial ulcer after endoscopic submucosal dissection with reference to Helicobacter pylori infection, CYP2C19 genotype, and tumor location: Multicenter randomized trial. Dig Endosc 28: 162-72, 2016.
  6. Miyajima H: Investigated and available therapeutic options for treating aceruloplasminemia. Expert Opinion on Orphan Drugs 3(9): 1011-1020, 2015.
  7. Miyajima H. Aceruloplasminemia. 2003 Aug 12 [Updated 2015 Nov 5]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1493/
  8. Kono S, Miyajima H. Aceruloplasminemia. In: Rosenberg RN, Pascual JM eds. Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease. Fifth Edition. Elsevier, Academic Press, London, Chapter 45, p.495-506, 2015.
  9. Terada T, Kakimoto A, Yoshikawa E, Kono S, Bunai T, Hosoi Y, Sakao-Suzuki M, Konishi T, Miyajima H,Ouchi Y: The Possible Link between GABAergic Dysfunction and Cognitive Decline in a Patient with Idiopathic Hypoparathyroidism, Intern Med54: 2245-2250.
 
邦文総説など
  1. 宮嶋裕明：Q8.透析患者の急性期脳梗塞の特徴と薬剤の使い方を教えてください. 加藤明彦編著、いまさら訊けない！透析患者 薬剤の考え方、使い方. 中外医学社. p. 148-152, 2015. 
  2. 宮嶋裕明：Wernicke脳症. 金澤一郎、永井良三（編）今日の診断指針 第7版. 医学書院. p.616-617, 2015.
  3. 林久男、宮嶋裕明：鉄欠乏性貧血と鑑別すべき二次性貧血(ii)亜鉛と銅の欠乏による貧血. 日本鉄バイオサイエンス学会治療指針作成委員会（編）鉄剤の適正使用による貧血治療指針.改訂[第3版].響文社. P.30-32, 2015.
  4.  

一覧に戻る